VIRTUAL PRESS OFFICESTM   (011) 807 3294   itnews@itweb.co.za | Advertise on ITWeb   Thu, 18 Dec, 07:58:22 AM
You are here Home Innovations

HP, African social enterprise mPedigree Network fight counterfeit drugs in Africa

Free consumer text messaging service targets counterfeit pharmaceutical market that causes at least 700 000 deaths per year globally.

HP and African social enterprise, mPedigree Network, have introduced a potentially life-saving service that targets counterfeit pharmaceuticals by enabling people in Nigeria and Ghana to easily check the authenticity of their malaria medication.

With the new service, patients taking a range of medication manufactured by May & Baker Nigeria PLC and the KAMA Group of Ghana can send a free text message to get an instant response as to whether the tablets or syrup bottles they received are genuine.

Counterfeit medicines often contain the wrong quantity of active pharmaceutical ingredients, which can result in illness or death. The system from HP and mPedigree assigns a code that is revealed by scratching off a coating on the drugs' packaging. This code can be text messaged by the consumer or medical professional to a free SMS (short message service) number to verify the authenticity of the drug.

If the drug packaging contains a counterfeit code, the consumer will receive a message alerting them that the pack may be a fake, as well as a phone number to report the incident. Pharmaceutical safety regulators in Ghana and Nigeria are working to ensure that the concerns of users are promptly addressed.

“Counterfeit pharmaceuticals are a big problem for developing nations, particularly in Africa. It is important that we developed an African solution to an African problem, using the resources and technologies that are widely available and easy to implement,” said Bright Simons, founder, mPedigree Network. “It's absolutely imperative that people can trust the authenticity of the drugs they are consuming, and this system will give them an easy and effective way of doing so.”

The service is funded by the participating pharmaceutical companies. May & Baker Nigeria has already begun supplying its extensive distribution network of chemists and clinics across Nigeria with medicines that are packaged with codes. The current deployment covers three of the company's lines of anti-malarial (artelum), anti-amoebicide (loxagyl) and analgesic (easadol) medication.

“Over the years, we have invested a huge amount of time and money in developing drugs which will protect the health of people around the world,” said Dr Joseph Ikemefuna Odumodu, chief executive, May & Baker Nigeria, and president, West African Pharmaceutical Manufacturers Association. “It's in both our and our customers' interest that they receive the full benefit of that investment. This system will safeguard both of us now and in the future.”

HP is providing the hosting infrastructure for the service, as well as the security and integrity systems, through its data centres in Frankfurt, Germany. mPedigree Network is providing the business process interfaces that allow pharmaceutical companies to code their products for the system and to monitor use of genuine and counterfeit drugs.

The service, which was recently endorsed by the West African Health Organisation, is expected to be available for other medications and in more countries in the near future. All GSM mobile network operators in Ghana and Nigeria are signatories to the scheme.

“Technology plays a critical role in solving many serious health problems around the world,” said Clive Brindley, Solutions Architect, HP Software and Solutions, South Africa. “While Nigeria and Ghana are the starting points for this programme, we are working to create a scalable infrastructure to be leveraged by other regions where counterfeit medicine is a growing issue.”

Background on counterfeit drugs

The World Health Organisation estimates that counterfeit drugs constitute:

* Approximately 10% of the global drug market(1)
* Twenty-five percent of the drug market in developing countries(2)

Use of counterfeit drugs is estimated to:

* Cause at least 700 000 deaths per year(3)
* Finance a $75 billion global counterfeit pharmaceutical industry in 2010(4)

Counterfeit drugs also have a severe impact on the pharmaceutical industry, with manufacturers suffering economic losses from patent and copyright infringement. In Nigeria alone, hundreds of thousands of medicine buyers can benefit from the technology as up to 6 million packs could be integrated into the service over the coming year.

Supporting resources:

* Post on Data Central, the official HP corporate blog, which includes an embeddable infographic containing facts and figures about counterfeit drugs, mobile adoption and health in the developing world: http://www.hp.com/go/datacentral
* Video interview with Bright Simons, founder of mPedigree Network: http://www.youtube.com/hptalks
* Visual representations of the mPedigree solution available for download: http://www.flickr.com/photos/hpnews

More information about HP's work in innovation for healthcare is available at http://www.hp.com/hpinfo/globalcitizenship/globalissues/healthcare.html.

May & Baker Nigeria

As Nigeria's first pharmaceutical company, May & Baker has for over six decades remained a key player in West Africa's healthcare industry. In 2010, the company commissioned the first World Health Organisation (WHO) standard pharmaceutical plant in Nigeria, and one of the largest plants in Africa. Having earned the much coveted NIS ISO 9001: 2000 certificate for its quality management system in 2008, May & Baker has become recognised as a pharmaceutical company at the very forefront of innovation in the region and across the continent. The company is the recipient of the prestigious 2007 prize of excellence in pharmaceutical manufacturing from the Nigerian Federal Ministry of Health. More at http://www.may-baker.com.

mPedigree

mPedigree Network partners with the principal telecom operators in Africa, the leading pharmaceutical industry associations on the continent and Fortune 500 technology powerhouses to empower African patients and consumers to protect themselves from the fatal effects of pharmaceutical counterfeiting, which kills nearly a million people a year, and maims countless more, in vulnerable parts of the world. As a social enterprise, and a member of the Ashoka and World Economic Forum communities, we owe equal duty to our consumer clients, pharmaceutical clients, impact investors and regulatory allies. More information about mPedigree is available at http://mpedigree.net.

HP

HP creates new possibilities for technology to have a meaningful impact on people, businesses, governments and society. The world's largest technology company, HP brings together a portfolio that spans printing, personal computing, software, services and IT infrastructure to solve customer problems. More information about HP (NYSE: HPQ) is available at http://www.hp.co.za.

(1) “WHO Drug Information, Volume 20, Number 1, 2006” World Health Organisation
(2) “Standard and Counterfeit Medicines,” World Health Organisation. Nov. 2003
(3) “Keeping It Real: Protecting the world's poor from fake drugs,” International Policy Network, May 2009 (Approximately 700 000 deaths from malaria and tuberculosis alone are attributable to fake drugs.)
(4) “21st Century Health Care Terrorism: The Perils of International Drug Counterfeiting,” Centre for Medicine in the Public Interest, Sept. 2005

This news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of HP and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements of the plans, strategies and objectives of management for future operations; any statements concerning expected development, performance or market share relating to products and services; any statements regarding anticipated operational and financial results; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Risks, uncertainties and assumptions include macroeconomic and geopolitical trends and events; the execution and performance of contracts by HP and its customers, suppliers and partners; the achievement of expected operational and financial results; and other risks that are described in HP's Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2010 and HP's other filings with the Securities and Exchange Commission, including but not limited to HP's Annual Report on Form 10-K for the fiscal year ended October 31, 2009. HP assumes no obligation and does not intend to update these forward-looking statements.

© 2010 Hewlett-Packard Development Company, L.P. The information contained herein is subject to change without notice. HP shall not be liable for technical or editorial errors or omissions contained herein.

 

Editorial contacts

HP
Hedy Gorton
(+27) 11 785 1000
This e-mail address is being protected from spambots, you need JavaScript enabled to view it

 

Our comments policy does not allow anonymous postings. Read the policy here



 

 

 

Sponsors Message